Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 12/20 | 0.43 |
| ▸ | DRD3 | P35462 | 12/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13872514 | 1.00 | TRPV4 (0.49) | TRPV4DRD2DRD3DRD4CTSL | |
| SCHEMBL4132366 | 0.88 | TRPV4 (0.49) | TRPV4CTSLMAPTCAPN1 | |
| SCHEMBL14605683 | 0.86 | TRPV4 (0.47) | TRPV4CTSLCAPN1 | |
| SCHEMBL4132372 | 0.86 | TRPV4 (0.47) | TRPV4CTSLCAPN1 | |
| SCHEMBL13872524 | 0.86 | TRPV4 (0.47) | TRPV4CTSLCAPN1 | |
| SCHEMBL4136044 | 0.79 | TRPV4 (0.52) | TRPV4CTSL | |
| SCHEMBL4139857 | 0.78 | TRPV4 (0.55) | TRPV4CTSL | |
| SCHEMBL4127488 | 0.78 | TRPV4 (0.76) | TRPV4DRD2DRD3CTSL | |
| SCHEMBL4127926 | 0.78 | TRPV4 (0.76) | TRPV4DRD2DRD3CTSL | |
| SCHEMBL4552230 | 0.77 | TRPV4 (0.76) | TRPV4DRD2DRD3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885DRD2 829/4885DRD3 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.